Introduction
Psoriasis is a chronic inflammatory skin disease mediated by immune cells. Worldwide prevalence of psoriasis is approximately 2-3%, 1 and prevalence in China varies between 0.13% and 1.23%. 2 The most common type of psoriasis, accounting for 90% of all cases, is psoriasis vulgaris, 3 in which red coloured papulosquamous plaques are well-delineated from the surrounding normal skin, and are covered by white or silvery scales. Psoriasis is recurrent, and associated with a variety of comorbidities including cardiovascular diseases, diabetes mellitus, obesity and even hyperlipidaemia, and seriously affects patients' quality of life. 4, 5 However, the mechanism underlying the pathogenesis of psoriasis remains largely unknown.
Psoriasis development is accompanied by the enhanced expression of cytokines, 6 such as interferon (IFN)-gamma, interleukin (IL)-2, and IL-22.
7,8 IL-22 is mainly produced from activated T cells and natural killer (NK) cells, and sequentially induces the rapid proliferation of keratinocytes, which specifically express the IL-22 receptor, thus leading to the pathogenesis of psoriasis. 9 Additionally, high levels of IL-22 have been detected in the sera of patients with psoriasis, and have been positively correlated with disease severity. 10 Keratinocyte cell lines induced by IL-22, for example, HaCaT cells, are often used as models for the study of psoriasis. 11 Moreover, lines of evidence reveal that activation of the signal transducer and activator of transcription 3 (STAT3) has been involved in cytokine expression and the development of psoriasis. [12] [13] [14] Tetrandrine (Tet) is a natural nonselective Ca 2þ channel blocker with antiinflammatory effects. 15, 16 It is widely used in the treatment of rheumatism, joint pain, neuralgia and cancer, [17] [18] [19] however, the effect of Tet on psoriasis remains unclear.
The aim of the present study was to measure the in vitro antiproliferative effect of Tet on HaCaT cells, and to analyse the effect of Tet on STAT3 expression and phosphorylated (P)-STAT3 levels and cytokine production in HaCaT cells induced by IL-22 using reverse transcription and realtime quantitative polymerase chain reaction (qPCR), Western blot and enzyme-linked immunosorbent assay (ELISA). 
Materials and methods

Cell culture and treatment
MTT assay
The HaCaT cells in logarithmic growth phase were harvested and seeded into 96-well plates at 2 Â 10 3 cells per well in complete medium and incubated at 37 C/5% CO 2 to allow cells to adhere. The medium was then replaced with complete medium containing Tet and/or IL-22, or complete medium only (control). Three replicates were set up for each group. Following incubation for 24-72 h, the medium was replaced with serum-free medium containing 5 mg/ml MTT (Cat No. C0009; Beyotime, Shanghai, China) and the cells were incubated for a further 4 h at 37 C/5% CO 2 . Finally, the crystals were dissolved by the addition of dimethyl sulphoxide and the absorbance value at 490 nm was measured using a micro-plate reader. Inhibition of cell proliferation by Tet was calculated as % inhibition ¼ (1-A Tet / A control ) Â 100 (where A ¼ absorbance value at 490 nm). The half maximal inhibitory concentration (IC50) was calculated using SPSS software, version 21.0 (SPSS Inc., Chicago, IL, USA).
Western blot
Interleukin-22 is known to activate janus kinase (JAK)-STAT3, extracellular signalregulated kinase (ERK)1/2/mitogen-activated protein kinase (MAPK), and p38/ MAPK pathways to regulate the proliferation and differentiation of keratinocytes after binding to its receptor. 20 Therefore, to clarify the mechanism underlying the inhibition of HaCaT cell proliferation by Tet, protein levels of P-STAT3 and STAT3 were measured. The HaCaT cells in logarithmic growth phase were harvested and seeded into 6-well plates at a density of 2 Â 10 6 cells/ well in complete medium and incubated at 37 C/5% CO 2 to allow cells to adhere. The medium was then replaced with complete medium containing Tet and/or IL-22, or complete medium only (control). Experiments were performed in triplicate. Following incubation at 37 C/5% CO 2 for 72 h, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (Cat No. P0013B; Beyotime) and total protein concentration was measured using a bicinchoninic acid (BCA) protein assay kit (Cat No. RTP7102; RealTimes Biotechnology Co., Ltd., Beijing, China). Proteins (20 mg) were separated by 10% sodium dodecyl sulphate (SDS)-polyacrylamide-gel electrophoresis (PAGE) and transferred to a polyvinylidene difluoride membrane. After blocking with 5% bovine serum albumin BSA, the membrane was incubated with primary antibodies (anti-P-STAT3 
RNA isolation, reverse transcription and real-time qPCR
Total RNA was extracted from HaCaT cells (in 6-well plates) that had been exposed to complete medium containing Tet and/or IL-22, or complete medium only (control), using TriZol reagent (Cat No. 10606ES60; YEASEN, Shanghai, China). Total RNA quality was assessed by agarose gel electrophoresis and the concentration was measured using a NanoDrop ND-1000 spectrophotometer (Thermo scientific, Basingstoke, UK). The cDNA was synthesized from 1 mg RNA using TIANScript II cDNA kit (Cat No. KR107; TIANGEN, Beijing, China) according to the manufacturer's protocol. Gene expression levels were quantified by real-time qPCR using an iQ5 real-time qPCR instrument (Bio-Rad) and a 20-ml reaction mix comprising 7 ml ddH 2 0, 2 ml cDNA, 10 ml SuperReal PreMix (SYBR Green 
ELISA
In addition to keratinocyte proliferation, the inflammatory response is also shown to be amplified during the development of psoriasis. 21 As stated previously, the expression of pro-inflammatory factors, such as TNF-a, IL-6, IL-8, IL-20, and chemokine (C-C motif) ligand 20 (CCL20) was significantly up-regulated in the epidermis of psoriasis patients. 9, 22, 23 Thus, the production of these cytokines by HaCaT cells was investigated following treatment with IL-22 alone or with the addition of Tet.
Supernatant from HaCaT cells that had been incubated with Tet and/or IL-22 for 72 h at 37 C/5% CO 2 was harvested and cell debris was removed by centrifugation at 1 000 Â g for 10 min. Levels of TNF-a, IL-6, IL-8, IL-20 and CCL20 in the supernatants were measured using the following Taiwan] ) following the manufacturer's instructions. Briefly, 50 ml of standard, samples and blank were added to the well of a 96-well plate coated with the primary antibodies against the cytokines. The HRP-conjugated detection antibodies (100 ml) were then added and incubated for 1 h at 37 C. After washing five times, substrates A and B were added for a further 15-min incubation. Finally, the absorbance at 450 nm was read in a micro-plate reader immediately after adding the stop solution. A standard curve was produced to quantify the concentration of cytokines from the different samples.
Statistical analyses
Data are presented as mean AE SD and were analysed using SPSS software, version 21.0 (SPSS Inc.). Between-group comparisons were performed with analysis of variance (ANOVA) after performing a test for normality. Fisher's least significant difference (LSD) and Student-Newman-Keuls (SNK) tests were used when there was homogeneity of variance, otherwise, Tamhane's T2 or Dunnett's T3 tests were used. A P value < 0.05 was considered to be statistically significant.
Results
Tet inhibits the proliferation induced by IL-22 in HaCaT cells
The effect of Tet on proliferation of HaCaT cells was initially investigated at Tet concentrations of 40, 60, 80, 120, 160, and 240 mM incubated for 48 h. HaCaT proliferation was found to be inhibited by Tet in a dose-dependent manner, with increasing Tet concentrations resulting in increased inhibition of proliferation (Figure 1a) . The IC50 value was calculated to be 86.02 AE 6.45 mM.
The possible role of Tet in the inhibition of proliferation by HaCaT cells treated with IL-22 was explored using Tet at 86 mM (the IC50 value; high Tet), and at 43 mM (half of the IC50 value; low Tet). Following treatment with IL-22 only for 72 h, the 490 nm absorbance values increased in all groups over time (Figure 1b) . In the groups treated with IL-22 and either high (86 mM) or low (43 mM) Tet concentrations, the proliferation of HaCaT cells was significantly decreased at 72 h (Figure 1b) . Moreover, the inhibition of proliferation was higher in the high Tet group compared with low Tet group (P < 0.05; Figure 1b) , suggesting that proliferation of HaCaT cells may be inhibited by Tet in a dose-dependent manner.
Tet reduces IL-22 induced STAT3 phosphorylation in HaCaT cells
The level of P-STAT3 protein was significantly up-regulated after 72-h incubation with IL-22 only, and this increased level of P-STAT3 was significantly reduced by coincubation with Tet at both 43 and 86 mM concentrations (P < 0.05; Figure 2a and b) . In addition, the reduced level of P-STAT3 was significantly higher with the higher Tet concentration (P < 0.05 versus 43 mM Tet; Figure 2a and b) . STAT3 protein and mRNA levels were not significantly changed by IL-22 with or without Tet (Figure 2c and d) , suggesting that Tet may inhibit the promotion of STAT3 phosphorylation by IL-22, which may contribute to the inhibition of HaCaT cell proliferation.
Tet reduces IL-22 induced cytokine production in HaCaT cells
Levels of TNF-a, IL-6, IL-8, IL-20 and CCL20 proteins in the supernatant of HaCaT cells were all increased following 72-h incubation with IL-22 only (Figure 3a-e) . When co-incubated with Tet, the enhanced production of cytokines by IL-22 was significantly reduced in a dose-dependent manner (Figure 3a-e) , suggesting that Tet may inhibit the production 
Discussion
As a chronic inflammatory skin disease, psoriasis affects 2-3% of individuals worldwide, and seriously compromises the quality of life of patients.
1,4,5 IL-22 signalling is considered to play an important role in psoriasis, since IL-22 expression is highly positively correlated with disease severity 10 and IL-22 receptors are specifically expressed in keratinocytes. 9 Tet, as an anti-inflammation drug, is widely used in clinics in China, 24 however, the role of Tet in psoriasis remains to be demonstrated.
In the present study, Tet was demonstrated to have a dose-dependent inhibitory effect on the in vitro proliferation of HaCaT cells, and was shown to reduce STAT3 phosphorylation levels induced by IL-22 without affecting STAT3 mRNA and protein levels. Furthermore, co-incubation of Tet with IL-22 significantly downregulated the IL-22 induced production of TNF-a, IL-6, IL-8, IL-20 and CCL20 by HaCaT cells.
Signal transducer and activator of transcription 3 (STAT3) has been reported to mediate the expression of a variety of genes in cellular processes, such as cell growth and apoptosis. 25 One important finding of the present study was that IL-22 induced P-STAT3 in HaCaT cells was notably reduced by coincubation with Tet. Combined with the result that Tet was shown to inhibit HaCaT cell proliferation, it would make sense for future studies to verify the potential role of P-STAT3 in Tet-mediated antiproliferation effects.
In conclusion, Tet was found to greatly reduce the in vitro production of IL-22-induced TNF-a, IL-6, IL-8, IL-20 and CCL20 by HaCaT cells. Combined with the results that Tet was shown to inhibit HaCaT cell proliferation, the present authors hypothesize that the antiinflammatory role of Tet may be associated with its inhibitory effect on cell proliferation. Therefore, developing an effective drug such as Tet may be a good strategy to target the rapid proliferation of keratinocytes and the enhanced expression of inflammatory mediators in psoriasis.
Collectively, the present study demonstrates the role of Tet in the in vitro inhibition of proliferation and cytokine production by HaCaT cells, and STAT3 phosphorylation may be involved in this process. The present findings expand our understanding of the diverse functions of Tet and contribute to developing new strategies for psoriasis treatment.
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